RICERCA ITALIANA     

FIRB simili:

• 1 - Approcci combinati di terapia genica nel trattamento del glioblastoma
• 2 - BILANCIO OSPITE-TUMORE NELLA TERAPIA MEDICA DELLE NEOPLASIE: RUOLO DI NF-kB
• 3 - Progettazione, sintesi e screening biologico con metodi ad alta resa di librerie combinatoriali di molecole sviluppate a partire da unità strutturali originali, per applicazioni in campo terapeutico e diagnostico
• 4 - Studio dell'identità cellulare e dei meccanismi di differenziazione cellulare nell'era della postegnomica utilizzando tre situazioni paradigmatiche: la mammella, l'osso e i linfociti
• 5 - Modelli transgenici per malattie ad eziologia complessa
• 6 - Sviluppo di molecole innovative in grado di curare malattie neurodegenerative e neuroinfiammatorie.
• 7 - Ectoenzimi leucocitari e loro coinvolgimento nella patogenesi, diagnosi e terapia di selezionate patologie umane
• 8 - Metodologie Innovative di Risonanza Magnetica (RM) in Patologie Tumorali e Cardiovascolari
• 9 - Riconoscimento molecolare e funzionalità cellulare
• 10 - Metodologie per l'individuazione e lo sviluppo di molecole in grado di interferire specificamente con bersagli critici per la terapia di malattie

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze chimiche
  • CHIMICA ORGANICA
• Area scientifico disciplinare: Scienze biologiche
  • BIOCHIMICA
• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA GENERALE

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

Classificazione geografica

• Regione: Lombardia

Bibliografia

1. For instance see: Gordon M.A. et al J.Med.Chem. 1385, 10 (1994); Balkenhol et al Angew. Chem. Int. Ed. Engl. 2288 (1996); Rademann J., Jung G. Science 287, 1947 (2000); Thompson. L.A. Curr. Opinion in Chem. Biol. 4, 324 (2000).
2. Schreiber S. L. Science 287, 1964 (2000).
3. For a recent review, see: Alaimo P.J., Shogren-Knaak M.A., Shokat K.M. Curr. Opinion in Chem. Biol. 5, 360 (2001).
4. Rockwell M.M. et al. J. Am. Chem. Soc. 118, 10337 (1996); Rongze K. et al. J. Am. Chem. Soc. 121, 8128 (1999).
5. Fast docking Abagayan R., Totrov M. Curr. Opinion in Chem. Biol. 5, 375 (2001).
6. Studt T. Drug Discovery and Development (2000).
7. Ghose A.K., Viswanadhan V.N., Wendoloski J.J. J. Comb. Chem. 1, 55 (1999).
8. Giovannoni G, Haltung P. Curr. Opinion Neurol 9, 165 (1996), Ferrante P. et al J.Immunol 160, 1514 (1998)
9. Caimi G. et al J. Neurol Science 1, 186(1-2): 23 (2001)
10. Vedder N.B. et al Proc Natl Acad Sci USA 87, 2643 (1990)
11. Humphries M.J. Biochem. Soc. Trans. 28, 311 (2000).
12. Giancotti F.G., Ruoslahti E. Science 285, 1028 (1999).
13. Giancotti, F.G. Nat. Cell Biol. 2, E13 (2000); Eliceiri B.P., Cheresh D. A Curr. Opinion in Cell Biol. 13, 563 (2001).
14. Xiong J.-P. et al. Science, 294, 339 (2001).
15. Kerr J.S., Slee A.M., Mousa S.A. Expert Opinion on Investigational Drugs 9, 1271 (2000).
16. Ruoslahti E., Pierschbacher M.D. Science 238, 491 (1987).
17. Haubner R., Finsinger D., Kessler H. Angew. Chem. Int. Ed. Engl. 36, 1374 (1997), Bach II A.C., Espina J.R., Jackson S.A., Stouten P.F.W., Duke J.L., Mousa S.A., DeGrado W.F. J. Am. Chem. Soc. 118, 293 (1996).
18. Belvisi L., Bernardi A., Checchia A., Manzoni L., Potenza D., Scolastico C., Castorina M., Cupelli A., Giannini G., Carminati P., Pisano C. Org. Lett. 3, 1001 (2001).
19. Pisano C., Cupelli A., Castorina M., Giannini G., Marcellini M., Riccioni T., Vesci L., Carminati P., Belvisi L., Bernardi A., Manzoni L., Potenza D., Scolastico C. International School of Pharmacology, 63rd Course “Angiogenesis and Signal Transduction in Anti-Cancer Drug Development”, Erice, 25-30 aprile 2001, Abstract Book p.22 (Oral Communication)
20. Calabresi et al Biochem. Biophys. Res. Comm. 238, 61 (1997).
21. Speciale L. et al Immunology 93,109 (1998).
22. Speciale L. et al. Clinical Sci, in press 2001
23. Dechantsreiter M.A. et al J. Med. Chem. 42, 3033 (1999); Haubner R., Schmitt W., Hoelzemann G., Goodman S.L., Jonczyk A., Kessler H. J. Am. Chem. Soc. 118, 7881 (1996).
24. Gendler S. et al. J. Biol. Chem. 263, 12820 (1988); Zotter S. et al. Cancer Rev. 11, 55 (1988); Girling A. et al. Int. J. Cancer 43, 1072 (1989).
25. Apostolopoulos V. et al. Crit. Rev. Immunol. 14, 293 (1995); Finn O.J. et al. Immunol. Rev. 145, 61 (1995).
26. Hiltbold E.M. et al. J. Immunol. 165, 3730 (2000).
27. Gendler S.J. et al. J. Biol. Chem. 265, 15286 (1990).
28. Bramwell M.E. et al. J. Cell Sci. 86, 249 (1986).
29. Gendler S.J. et al. Annu. Rev. Physiol. 57, 607 (1995).
30. Hanisch F.G. et al. Eur. J. Biochem. 236, 318 (1996).
31. Burchell J. et al. Cancer Res. 47, 5476 (1987).
32. Gendler S.J. et al. Annu. Rev. Physiol. 57, 607 (1995).
33. Jerome K.R. et al. Cancer Res. 51, 2908 (1991); Kotera, Y. et al. Cancer Res. 54, 2856 (1994).
34. Magarian-Blander J. et al. J. Immunol. 160, 3111 (1998); Apostolopoulos V. et al. Eur. J. Immunol. 27, 2579 (1997).
35. Hiltbold E.M. et al. Cell. Immunol. 194, 143 (1999).
36. Agrawal B. et al. Nat. Med. 4, 43 (1998).
37. Hiltbold E.M. et al. J. Immunol. 165, 3730 (2000).
38. Hiltbold E.M. et al. J. Immunol. 165, 3730 (2000).
39. Apostolopoulos V. et al. Vaccine 18, 3174 (2000).
40. Tan M.C. et al. Eur. J. Immunol. 27, 2426 (1997).
41. Engering A.J. et al. Eur. J. Immunol. 27, 2417 (1997).
42. West M., Blanchette C., Dressman H., Huang E., Ishida, S., Spang R., Zuzan H., Olson J.A.J., Marks J.R., Nevins J.R., Proc.Natl.Acad.Sci U.S.A., 98: 11462-11467, (2001).
43. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein L.P., Borresen-Dale A.L. Proc.Natl.Acad.Sci U.S.A., 98: 10869-10874, (2001).
44. Sommer S., Fuqua S.A., Semin.Cancer Biol., 11: 339-352, (2001).
45. Yoshida M., Abe O., Uchino J., Kikuchi K., Abe R., Enomoto K., Tominaga T., Fukami A., Sugimachi K., Nomura Y., Hattori T., Ogawa N. Breast Cancer, 4: 93-101, (1997).
46. Lundholt B.K., Briand P., Lykkesfeldt A.E. Breast Cancer Res.Treat., 67: 199-214, (2001).
47. Leonetti C., Biroccio A., Benassi B., Stringaro A., Stoppacciaro A., Semple S.C., Zupi G. Cancer Gene Ther., 8: 459-468, (2001).
48. Rudlowski C., Rath W., Becker A.J., Wiestler O.D., Buttner R. N.Engl.J.Med., 345: 997-998, (2001).
49. Moasser M.M., Basso A., Averbuch S.D., Rosen N. Cancer Res, 61: 7184-7188, (2001).
50. Nielsen PE, Egholm M, Berg RH, Buchardt O. Science 254: 1497-1500. (1991)
51. Nielsen PE, Haaima G. Chem. Soc. Rev 26: 73-78 . (1997);
52. Egholm M, Buchardt O, Nielsen PE, Berg RH. J. Am. Chem. Soc. 114: 1895-1897, (1992).)
53. Nelsen PE. Curr. Opin. Biotech. 12:16-20 [2001)
54. Nielsen P.E., Egholm M., Berg R.H., Buchardt O. Nucleic Acids Res.; 21:197-200 (1993)
55. Nielsen PE, Egholm M. Horizon Scientific Press (Wymondham,UK) (1999); Nielsen PE, Egholm M, Buchardt O. Gene 149:139-145, (1994)
56. Dieci G., Corradini R., Sforza S., Marchelli R., Ottonello S. J. Biol. Chem. 276:5720-5725, (2001)
57. Knudsen H, Nielsen PE, Anti-Cancer Drugs; 8: 113-118 (1997); Good L., Nature Biotech 16:355-358 (1998)
58. Pooga H., Soomets U., Hallbrink Valkna A., Saar K., Rezaei K., Kahl U., Hao J-X., Xu X-J Wiensenfeld-Hallin Z., Hockfelt T et al. Nature Biotechnol. 16:857 (1998); Cutrona G., Carpaneto EM., Ulivi M., Roncella S., Landt O., Ferrarini M., Boffa LC. Nature Biotech. 18:300-303, (2000)
59. Boffa L C., Scarfi S., Mariani M R., Damonte G., Allfrey V G., Benatti U., Morris P L., Cancer Res. 60: 2258-2262, (2000)).
60. Koch T., Hansen HF., Andersen P., Larsen T., Batz HG., Otteson K., Ørum H. J. Pept. Res., 49:80-88, (1997).
61. Dueholm KL., Nielsen PE., New J. Chem. 21: 19-31, (1997); Hyrup B., Egholm M., Nielsen PE., Wittung P., Nordén B., Buchardt O. J. Am. Chem. Soc. 116: 7964-7970, 1994
62. Falkiewicz B. Acta Chem. Polonica, 46:509-529 and reference therein,(1999); Sforza S., Corradini R., Galaverna G., Dossena A., Marchelli R. Minerva Biotech.; 11: 163-174, (1999) and reference therein].

Parole Chiave

Inibitori delle Integrine; Antigeni tumorali modificati; Estro-PNAs; Antitumorali per il cancro della mammella; Antiflogistici per il sistema nervoso centrale; Sintesi Organica